ESTRO 35 Programme book & Exhibition guide

152

SCIENTIFIC PROGRAMME

| PROGRAMME AND EXHIBITION GUIDE

INTERDISCIPLINARY RADIOBIOLOGY

CLINICAL BRACHYTHERAPY PHYSICS

RTT

YOUNG

TUESDAY 3 MAY 2016

Symposium

WBRT FOR BRAINMETASTASES- THE END OF AN ERA?

09:15 - 10:30 | GIALLA

This session will address an actual outline of the efficacy of whole brain radiotherapy (WBRT) in the

treatment of multiple brain metastases. First speaker, Paula Mulvenna, will give an overview of WBRT

including history, aims and toxicities. Additionally, she will shortly present the outcomes of the MRC

QUARTZ trial. Luis Schiappacasse will address the role of stereotactic radiosurgery to treat limited and

extensive brain metastases especially in conjunction with WBRT. Finally, Rafal Dziadziuszko will present

systemic therapies for the treatment of brain metastases originated from lung and breast cancer with

focus on chemotherapy alone or in combination with radiotherapy.

Chair: B. Timmermann (Germany)

Co-chair: D. Greto (Italy)

09:15 > Whole brain radiotherapy for brain metastases - the end of an era?

Speaker: P. Mulvenna (UK)

SP-0587

09:40 > Focal radiotherapy for multiple brain metastases

Speaker: L. Schiappacasse (Switzerland)

SP-0588

10:05 > Role of systemic therapy in the treatment of brain metastases

Speaker: R. Dziadziuszko (Poland)

SP-0589

Symposium

RADIOTHERAPY “AUTOVACCINATION”; WITH SYSTEMIC IMMUNE

MODULATORS FOR MODERN IMMUNOTHERAPY

09:15 - 10:30 | ROOM 4

The current understanding of the impact of radiation therapy on anti tumour immunity has changed

our understanding of tumour resistance to radiotherapy which is no longer perceived as the only conse-

quence of tumour cells intrinsic clonogenic resistance to cell kill.

The interplay between tumour cells and the immune stroma is influenced by cell death triggered by

irradiation which dictates the immunological response. Immune checkpoints inhibitors may increase

tumour response and also propagate systemic anti tumour immune response thus converting the

tumour into an immunogenic hub.

Chair: E. Deutsch (France)

Co-chair: M. Trovo (Italy)

09:15 > Should the combined treatment be part of our field of knowledge?

The 5

‘R’ (immune-mediated) rejection of radiobiology

Speaker: P.C. Lara Jimenez (Spain)

SP-0590

09:40 > Radiotherapy for immunotherapy: optimising the doses and fractiona-

tion

Speaker: S. Demaria (USA)

SP-0591